JAK inhibitors for the treatment of autoimmune and inflammatory diseases

COVID-19 infection and rheumatoid arthritis: Faraway, so close!

“…Older age, female sex, prednisone >7.5 mg/day, prior infection, and greater number of hospitalizations were associated with increased HZ V risk, whereas vaccination was associated with a lower risk [71]. More recent reports from RCTs conducted with novel JAK-1 selective inhibitors upadacitinib and filgotinib have basically confirmed the same trend, suggesting that the increase in HZV infections can be considered as a class effect of JAKis [72,73]. Although the exact mechanism by which HZV reactivation occurs in the context of JAK inhibition is unclear, the downregulation of both cell-mediated immunity and innate antiviral signaling through type I and II interferons (IFN) is likely to be involved [74].…”

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

“…JAK inhibitors (JAKi) are small molecules targeting the intracellular cytokine signaling [286]. There are a number of JAKi currently both used and under investigation for use in several autoimmune systemic diseases such as RA, PsO, PsA, some of which are also approved or under investigation in other indications [287].…”

Tofacitinib in rheumatoid arthritis: what is new?

“…Первым представителем класса ингибиторов JAK является тофацитиниб (ТОФА), который широко применяется в клинической практике для лечения РА [12,13]. Углубление знаний об иммунопатогенезе иммуновоспалительных ревматических заболеваний, роли JAK в регуляции иммунного ответа и воспаления, а также материалы, накопленные в процессе клинического применения ТОФА при РА, стимулировали разработку новых ингибиторов JAK и расширение показаний для их применения при других иммуновоспалительных ревматических и "неревматических" заболеваниях [8,[14][15][16].…”